Efficacy of 200 IU OnabotulinumtoxinA (Botulinum Toxin Type A) in Patients With Idiopathic
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Idiopathic Overactive Bladder Resistant to Anticholinergic Treatment
- Sponsor
- Hisar Intercontinental Hospital
- Enrollment
- 60
- Locations
- 2
- Primary Endpoint
- frequencies of urination, nocturia, incontinence episodes
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
This study aimed to assess the efficacy and safety of onabotulinumtoxinA (botulinum toxin type A) in patients with idiopathic overactive bladder (OAB) and urinary incontinence who had previously failed to respond to anticholinergic treatment. Additionally, we examined the impact of significant reductions in bladder wall thickness on therapeutic outcomes.
Detailed Description
The efficacy of OnabotulinumtoxinA was investigated in patients who attended urology outpatient clinics between January 2016 and June 2022 for overactive bladder unresponsive to anticholinergic therapy. Baseline symptoms and quality of life data were compared to those at month 6 after the treatment. The voiding diary (for 3 days) of each patient was reviewed to assess and record patients' symptoms. Baseline ultrasound (US)-measured post-void residual urine (PVR) and bladder wall thickness (BWT) values were recorded. Patients with a history of neurological disorders, anticholinergic-naive patients, patients diagnosed with bladder cancer, and those with bladder outlet obstruction were excluded from the study.
Investigators
Basri Cakiroglu
Principal Investigator
Hisar Intercontinental Hospital
Eligibility Criteria
Inclusion Criteria
- •overactive bladder urge incontinence
Exclusion Criteria
- •neurological and/or neurosurgical disorders, anticholinergic-naive patients, bladder cancer, bladder stone, interstitial cystitis, prostate cancer chronic prostatitis bladder outlet obstruction
Outcomes
Primary Outcomes
frequencies of urination, nocturia, incontinence episodes
Time Frame: 1 years
below 8,above 8
urgency,
Time Frame: 1 years
present or absent